Harnessing the Power of Cannabis-Derived Ingredients for the Prescription Drug Market

As published in Terpenes and Testing

Everyone, from prominent politicians to billionaire business professionals, is lining up to capitalize on the economic value of the cannabis industry. But at Gb Sciences, we believe that cannabinoid-based medicines have significant economic potential, and we have created a therapeutic pipeline of cannabinoid-based therapeutics destined for the prescription drug market, not the cannabis market. Gb Sciences’ novel drug development program leverages the therapeutic potential of cannabinoid-containing mixtures for the treatment of severe medical conditions, and our cannabinoid-drug development programs are among the most advanced in the world.

Read the full article here.